HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

taurepar

Also Known As:

2-(1-phenylethylamino)ethanesulfonic acid isopropylamide hydrochloride

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Acyclic Hydrocarbons
    - Alkanes: 241
      - Alkanesulfonic Acids
        Taurine: 3452
        taurepar: 2
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Alkanesulfonic Acids
        Taurine: 3452
        taurepar: 2

Experts

1.	Sapronov, N S: 2 articles (12/2015 - 10/2010)
2.	Bul'on, V V: 1 article (12/2015)
3.	Krylova, I B: 1 article (12/2015)
4.	Selina, E N: 1 article (12/2015)
5.	Shabanov, P D: 1 article (12/2015)
6.	Fedotova, Yu O: 1 article (10/2010)
7.	Khnychenko, L K: 1 article (10/2010)
8.	Okunevich, I V: 1 article (10/2010)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/2015 - "The antiarrhythmic effect of taurepar, an N-phenylalkyl derivative of taurine, was examined in experiments on rats subjected to acute myocardial ischemia/reperfusion leading to arrhythmia development. " 12/01/2015 - "The antiarrhythmic potency of taurepar surpassed that of lidocaine during acute myocardial ischemia and that of propranolol during ischemia/reperfusion injury. " 10/01/2010 - "Experiments on rats with myocardial ischemia modeled by occlusion of the left coronary artery aggravated by alimentary dislipoproteinemia showed that therapy with taurepar (50 mg/kg), a taurine derivative, decreased blood corticosterone concentration and increased the level of endogenous testosterone, which attests to normalization of the compensatory-adaptive and gonadotropic functions of the organism."
2.	Ventricular Tachycardia 12/01/2015 - "During postischemic reperfusion, taurepar (25 mg/kg) did not prevent extrasystoles and ventricular tachycardia, but precluded the development of ventricular fibrillation and the death of animals. " 12/01/2015 - "During acute ischemia, taurepar (25 mg/kg) completely prevented early postocclusion arrhythmias including extrasystoles, ventricular tachycardia, and ventricular fibrillation. "
3.	Reperfusion Injury 12/01/2015 - "Antiarrhythmic Activity of Taurepar during Ischemic and Reperfusion Damage to Myocardium." 12/01/2015 - "The antiarrhythmic potency of taurepar surpassed that of lidocaine during acute myocardial ischemia and that of propranolol during ischemia/reperfusion injury. "
4.	Ventricular Fibrillation 12/01/2015 - "During postischemic reperfusion, taurepar (25 mg/kg) did not prevent extrasystoles and ventricular tachycardia, but precluded the development of ventricular fibrillation and the death of animals. " 12/01/2015 - "During acute ischemia, taurepar (25 mg/kg) completely prevented early postocclusion arrhythmias including extrasystoles, ventricular tachycardia, and ventricular fibrillation. "
5.	Ischemia 12/01/2015 - "During acute ischemia, taurepar (25 mg/kg) completely prevented early postocclusion arrhythmias including extrasystoles, ventricular tachycardia, and ventricular fibrillation. "

Related Drugs and Biologics

1.	Taurine
2.	Testosterone (Sustanon)
3.	Propranolol (Inderal)
4.	Lidocaine (Xylocaine)
5.	Corticosterone

Related Therapies and Procedures

1.	Therapeutics